The State of the Art and the Future of Precision Medicine: A Comprehensive Literature Review

Epstein, R. J., & Lin, F. P. (2017). Cancer and the omics revolution. Australian Family Physician, 46(4), 189–193.

Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J., & Ratain, M. J. (2013). Cancer pharmacogenomics: strategies and challenges. Nature Reviews. Genetics, 14(1), 23–34. https://doi.org/10.1038/nrg3352

Lakiotaki, K., Kanterakis, A., Kartsaki, E., Katsila, T., Patrinos, G. P., & Potamias, G. (2017). Exploring public genomics data for population pharmacogenomics. PloS One, 12(8), e0182138. https://doi.org/10.1371/journal.pone.0182138

Katsila, T., & Patrinos, G. P. (2015). Whole genome sequencing in pharmacogenomics. Frontiers in Pharmacology, 6, 61. https://doi.org/10.3389/fphar.2015.00061

Morganti, S., Tarantino, P., Ferraro, E., D’Amico, P., Duso, B. A., & Curigliano, G. (2019). Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Advances in Experimental Medicine and Biology, 1168, 9–30. https://doi.org/10.1007/978-3-030-24100-1_2

Dere, W. H., & Suto, T. S. (2009). The role of pharmacogenetics and pharmacogenomics in improving translational medicine. Clinical Cases in Mineral and Bone Metabolism : The Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases, 6(1), 13–16.

van der Wouden, C. H., Böhringer, S., Cecchin, E., Cheung, K.-C., Dávila-Fajardo, C. L., Deneer, V. H. M., Dolžan, V., Ingelman-Sundberg, M., Jönsson, S., Karlsson, M. O., Kriek, M., Mitropoulou, C., Patrinos, G. P., Pirmohamed, M., Rial-Sebbag, E., Samwald, M., Schwab, M., Steinberger, D., Stingl, J., … Guchelaar, H.-J. (2020). Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenetics and Genomics, 30(6), 131–144. https://doi.org/10.1097/FPC.0000000000000405

Relling, M. V, Klein, T. E., Gammal, R. S., Whirl-Carrillo, M., Hoffman, J. M., & Caudle, K. E. (2020). The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. Clinical Pharmacology and Therapeutics, 107(1), 171–175. https://doi.org/10.1002/cpt.1651

Cecchin, E., & Stocco, G. (2020). Pharmacogenomics and Personalized Medicine. In Genes (Vol. 11, Issue 6). https://doi.org/10.3390/genes11060679

Chenoweth, M. J., Giacomini, K. M., Pirmohamed, M., Hill, S. L., van Schaik, R. H. N., Schwab, M., Shuldiner, A. R., Relling, M. V, & Tyndale, R. F. (2020). Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. Clinical Pharmacology and Therapeutics, 107(1), 57–61. https://doi.org/10.1002/cpt.1664

Klein, M. E., Parvez, M. M., & Shin, J.-G. (2017). Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. Journal of Pharmaceutical Sciences, 106(9), 2368–2379. https://doi.org/10.1016/j.xphs.2017.04.051

Sullivan, P. F., Agrawal, A., Bulik, C. M., Andreassen, O. A., Børglum, A. D., Breen, G., Cichon, S., Edenberg, H. J., Faraone, S. V, Gelernter, J., Mathews, C. A., Nievergelt, C. M., Smoller, J. W., & O’Donovan, M. C. (2018). Psychiatric Genomics: An Update and an Agenda. The American Journal of Psychiatry, 175(1), 15–27. https://doi.org/10.1176/appi.ajp.2017.17030283

Lozupone, M., Seripa, D., Stella, E., La Montagna, M., Solfrizzi, V., Quaranta, N., Veneziani, F., Cester, A., Sardone, R., Bonfiglio, C., Giannelli, G., Bisceglia, P., Bringiotti, R., Daniele, A., Greco, A., Bellomo, A., Logroscino, G., & Panza, F. (2017). Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. Expert Review of Proteomics, 14(9), 809–824. https://doi.org/10.1080/14789450.2017.1375857

Kam, H., & Jeong, H. (2020). Pharmacogenomic Biomarkers and Their Applications in Psychiatry. Genes, 11(12). https://doi.org/10.3390/genes11121445

Hyman, D. M., Taylor, B. S., & Baselga, J. (2017). Implementing Genome-Driven Oncology. Cell, 168(4), 584–599. https://doi.org/10.1016/j.cell.2016.12.015

Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., Gogas, H., Mandalá, M., Haanen, J. B. A. G., Lebbé, C., Mackiewicz, A., Rutkowski, P., Nathan, P. D., Ribas, A., Davies, M. A., … Long, G. V. (2019). Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. The New England Journal of Medicine, 381(7), 626–636. https://doi.org/10.1056/NEJMoa1904059

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., Yamashita, T., Lu, Y.-S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A.-S., Mills, D., Wilke, C., Hirawat, S., & Juric, D. (2019). Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. The New England Journal of Medicine, 380(20), 1929–1940. https://doi.org/10.1056/NEJMoa1813904

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., … Solit, D. B. (2018). HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 554(7691), 189–194. https://doi.org/10.1038/nature25475

Doi, T., Shitara, K., Naito, Y., Shimomura, A., Fujiwara, Y., Yonemori, K., Shimizu, C., Shimoi, T., Kuboki, Y., Matsubara, N., Kitano, A., Jikoh, T., Lee, C., Fujisaki, Y., Ogitani, Y., Yver, A., & Tamura, K. (2017). Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. The Lancet. Oncology, 18(11), 1512–1522. https://doi.org/10.1016/S1470-2045(17)30604-6

Krop, I. E., Kim, S.-B., González-Martín, A., LoRusso, P. M., Ferrero, J.-M., Smitt, M., Yu, R., Leung, A. C. F., & Wildiers, H. (2014). Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet. Oncology, 15(7), 689–699. https://doi.org/10.1016/S1470-2045(14)70178-0

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., & Meyerson, M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, N.Y.), 304(5676), 1497–1500. https://doi.org/10.1126/science.1099314

Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., & Mano, H. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561–566. https://doi.org/10.1038/nature05945

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O’Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., & Chapman, P. B. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. The New England Journal of Medicine, 363(9), 809–819. https://doi.org/10.1056/NEJMoa1002011

Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., Kwak, E. L., Clark, J. W., Ryan, D. P., Deshpande, V., Dias-Santagata, D., Ellisen, L. W., Zhu, A. X., & Iafrate, A. J. (2012). Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. The Oncologist, 17(1), 72–79. https://doi.org/10.1634/theoncologist.2011-0386

Braig, Z. V. (2022). Personalized medicine: From diagnostic to adaptive. Biomedical Journal, 45(1), 132–142. https://doi.org/10.1016/j.bj.2019.05.004

Stevens, K. N., Vachon, C. M., & Couch, F. J. (2013). Genetic susceptibility to triple-negative breast cancer. Cancer Research, 73(7), 2025–2030. https://doi.org/10.1158/0008-5472.CAN-12-1699

Okugawa, Y., Grady, W. M., & Goel, A. (2015). Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology, 149(5), 1204-1225.e12. https://doi.org/10.1053/j.gastro.2015.07.011

Weber, C. E., & Kuo, P. C. (2012). The tumor microenvironment. Surgical Oncology, 21(3), 172–177. https://doi.org/10.1016/j.suronc.2011.09.001

Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews. Drug Discovery, 1(7), 493–502. https://doi.org/10.1038/nrd839

Rowley, J. D. (1973). Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243(5405), 290–293. https://doi.org/10.1038/243290a0

Siegel, R. L., Miller, K. D., & Jemal, A. (2015). Cancer statistics, 2015. CA: A Cancer Journal for Clinicians, 65(1), 5–29. https://doi.org/10.3322/caac.21254

Zhang, P.-Y., & Yu, Y. (2019). Precise Personalized Medicine in Gynecology Cancer and Infertility. Frontiers in Cell and Developmental Biology, 7, 382. https://doi.org/10.3389/fcell.2019.00382

Noyes, N., Knopman, J. M., Long, K., Coletta, J. M., & Abu-Rustum, N. R. (2011). Fertility considerations in the management of gynecologic malignancies. Gynecologic Oncology, 120(3), 326–333. https://doi.org/10.1016/j.ygyno.2010.09.012

Barroilhet, L., & Matulonis, U. (2018). The NCI-MATCH trial and precision medicine in gynecologic cancers. Gynecologic Oncology, 148(3), 585–590. https://doi.org/10.1016/j.ygyno.2018.01.008

Horowitz, N., & Matulonis, U. A. (2012). New biologic agents for the treatment of gynecologic cancers. Hematology/Oncology Clinics of North America, 26(1), 133–156. https://doi.org/10.1016/j.hoc.2011.11.002

NCCN guiedlines. (n.d.). https://www.nccn.org/professionals/physician_gls/default.aspx

Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., Zeaiter, A., Mitry, E., Golding, S., Balas, B., Noe, J., Morcos, P. N., & Mok, T. (2017). Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 377(9), 829–838. https://doi.org/10.1056/NEJMoa1704795

Planchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., Rigas, J. R., Upalawanna, A., D’Amelio, A. M. J., Zhang, P., Mookerjee, B., & Johnson, B. E. (2016). Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. The Lancet. Oncology, 17(7), 984–993. https://doi.org/10.1016/S1470-2045(16)30146-2

Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., Doebele, R. C., Le, L. P., Zheng, Z., Tan, W., Stephenson, P., Shreeve, S. M., Tye, L. M., Christensen, J. G., Wilner, K. D., … Iafrate, A. J. (2014). Crizotinib in ROS1-rearranged non-small-cell lung cancer. The New England Journal of Medicine, 371(21), 1963–1971. https://doi.org/10.1056/NEJMoa1406766

Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., Haggstrom, D., Felip, E., Kim, J.-H., Frewer, P., Cantarini, M., Brown, K. H., Dickinson, P. A., Ghiorghiu, S., & Ranson, M. (2015). AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. The New England Journal of Medicine, 372(18), 1689–1699. https://doi.org/10.1056/NEJMoa1411817

Hamburg, M. A., & Collins, F. S. (2010). The path to personalized medicine. The New England Journal of Medicine, 363(4), 301–304. https://doi.org/10.1056/NEJMp1006304

McLeod, H. L. (2013). Cancer pharmacogenomics: early promise, but concerted effort needed. Science (New York, N.Y.), 339(6127), 1563–1566. https://doi.org/10.1126/science.1234139

Filipski, K. K., Mechanic, L. E., Long, R., & Freedman, A. N. (2014). Pharmacogenomics in oncology care. Frontiers in Genetics, 5, 73. https://doi.org/10.3389/fgene.2014.00073

Hertz, D. L., & Rae, J. (2015). Pharmacogenetics of cancer drugs. Annual Review of Medicine, 66, 65–81. https://doi.org/10.1146/annurev-med-053013-053944

Patel, J. N. (2015). Cancer pharmacogenomics: implications on ethnic diversity and drug response. Pharmacogenetics and Genomics, 25(5), 223–230. https://doi.org/10.1097/FPC.0000000000000134

Ikediobi, O. N. (2008). Somatic pharmacogenomics in cancer. The Pharmacogenomics Journal, 8(5), 305–314. https://doi.org/10.1038/tpj.2008.8

Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., Burton, E. A., Wong, B., Tsang, G., West, B. L., Powell, B., Shellooe, R., Marimuthu, A., Nguyen, H., Zhang, K. Y. J., … Nolop, K. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 467(7315), 596–599. https://doi.org/10.1038/nature09454

Mehmood, S., Faheem, M., Ismail, H., Farhat, S. M., Ali, M., Younis, S., & Asghar, M. N. (2022). “Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics”. Frontiers in Molecular Biosciences, 9, 783494. https://doi.org/10.3389/fmolb.2022.783494

Zhao, Y., Healy, B. C., Rotstein, D., Guttmann, C. R. G., Bakshi, R., Weiner, H. L., Brodley, C. E., & Chitnis, T. (2017). Exploration of machine learning techniques in predicting multiple sclerosis disease course. PloS One, 12(4), e0174866. https://doi.org/10.1371/journal.pone.0174866

Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018). Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron, 97(4), 742–768. https://doi.org/10.1016/j.neuron.2018.01.021

Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F. D., Montalban, X., O'Connor, P., Sandberg-Wollheim, M., Thompson, A. J., Waubant, E., Weinshenker, B., & Wolinsky, J. S. (2011). Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology, 69(2), 292–302. https://doi.org/10.1002/ana.22366

Can Demirdöğen B. (2021). A literature review of biosensors for multiple sclerosis: Towards personalized medicine and point-of-care testing. Multiple sclerosis and related disorders, 48, 102675. https://doi.org/10.1016/j.msard.2020.102675

Sundström, P., Juto, P., Wadell, G., Hallmans, G., Svenningsson, A., Nyström, L., Dillner, J., & Forsgren, L. (2004). An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology, 62(12), 2277–2282. https://doi.org/10.1212/01.wnl.0000130496.51156.d7

Tizaoui K. (2018). Multiple sclerosis genetics: Results from meta-analyses of candidate-gene association studies. Cytokine, 106, 154–164. https://doi.org/10.1016/j.cyto.2017.10.024

Leu, C., Stevelink, R., Smith, A. W., Goleva, S. B., Kanai, M., Ferguson, L., Campbell, C., Kamatani, Y., Okada, Y., Sisodiya, S. M., Cavalleri, G. L., Koeleman, B. P. C., Lerche, H., Jehi, L., Davis, L. K., Najm, I. M., Palotie, A., Daly, M. J., Busch, R. M., & Lal, D. (2019). Polygenic burden in focal and generalized epilepsies. Brain : A Journal of Neurology, 142(11), 3473–3481. https://doi.org/10.1093/brain/awz292

Niestroj, L.-M., Perez-Palma, E., Howrigan, D. P., Zhou, Y., Cheng, F., Saarentaus, E., Nürnberg, P., Stevelink, R., Daly, M. J., Palotie, A., & Lal, D. (2020). Epilepsy subtype-specific copy number burden observed in a genome-wide study of 17 458 subjects. Brain : A Journal of Neurology, 143(7), 2106–2118. https://doi.org/10.1093/brain/awaa171

Kearney, H., Byrne, S., Cavalleri, G. L., & Delanty, N. (2019). Tackling Epilepsy With High-definition Precision Medicine: A Review. JAMA Neurology, 76(9), 1109–1116. https://doi.org/10.1001/jamaneurol.2019.2384

Sisodiya, S. M. (2021). Precision medicine and therapies of the future. Epilepsia, 62 Suppl 2(Suppl 2), S90–S105. https://doi.org/10.1111/epi.16539

Plecko B. (2013). Pyridoxine and pyridoxalphosphate-dependent epilepsies. Handbook of clinical neurology, 113, 1811–1817. https://doi.org/10.1016/B978-0-444-59565-2.00050-2

Mills, K. L., Lalonde, F., Clasen, L. S., Giedd, J. N., & Blakemore, S. J. (2014). Developmental changes in the structure of the social brain in late childhood and adolescence. Social cognitive and affective neuroscience, 9(1), 123–131. https://doi.org/10.1093/scan/nss113

Helbig, I., & Ellis, C. A. (2020). Personalized medicine in genetic epilepsies - possibilities, challenges, and new frontiers. Neuropharmacology, 172, 107970. https://doi.org/10.1016/j.neuropharm.2020.107970

Leach, E. L., Shevell, M., Bowden, K., Stockler-Ipsiroglu, S., & van Karnebeek, C. D. (2014). Treatable inborn errors of metabolism presenting as cerebral palsy mimics: systematic literature review. Orphanet journal of rare diseases, 9, 197. https://doi.org/10.1186/s13023-014-0197-2

Beavan, M. S., & Schapira, A. H. V. (2013). Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Annals of Medicine, 45(8), 511–521. https://doi.org/10.3109/07853890.2013.849003

Wang, L., Xie, C., Greggio, E., Parisiadou, L., Shim, H., Sun, L., Chandran, J., Lin, X., Lai, C., Yang, W.-J., Moore, D. J., Dawson, T. M., Dawson, V. L., Chiosis, G., Cookson, M. R., & Cai, H. (2008). The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience, 28(13), 3384–3391. https://doi.org/10.1523/JNEUROSCI.0185-08.2008

Bendikov-Bar, I., Maor, G., Filocamo, M., & Horowitz, M. (2013). Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells, Molecules & Diseases, 50(2), 141–145. https://doi.org/10.1016/j.bcmd.2012.10.007

Schapira, A. H. V, & Gegg, M. E. (2013). Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America, 110(9), 3214–3215. https://doi.org/10.1073/pnas.1300822110

Sun, Y., Liou, B., Xu, Y.-H., Quinn, B., Zhang, W., Hamler, R., Setchell, K. D. R., & Grabowski, G. A. (2012). Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. The Journal of Biological Chemistry, 287(6), 4275–4287. https://doi.org/10.1074/jbc.M111.280016

Yang, C., Rahimpour, S., Lu, J., Pacak, K., Ikejiri, B., Brady, R. O., & Zhuang, Z. (2013). Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proceedings of the National Academy of Sciences of the United States of America, 110(3), 966–971. https://doi.org/10.1073/pnas.1221046110

Mata, I. F., Leverenz, J. B., Weintraub, D., Trojanowski, J. Q., Chen-Plotkin, A., Van Deerlin, V. M., Ritz, B., Rausch, R., Factor, S. A., Wood-Siverio, C., Quinn, J. F., Chung, K. A., Peterson-Hiller, A. L., Goldman, J. G., Stebbins, G. T., Bernard, B., Espay, A. J., Revilla, F. J., Devoto, J., … Zabetian, C. P. (2016). GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson’s disease. Movement Disorders : Official Journal of the Movement Disorder Society, 31(1), 95–102. https://doi.org/10.1002/mds.26359

Qin, Q., Zhi, L.-T., Li, X.-T., Yue, Z.-Y., Li, G.-Z., & Zhang, H. (2017). Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission. CNS Neuroscience & Therapeutics, 23(2), 162–173. https://doi.org/10.1111/cns.12660

Kasten, M., & Klein, C. (2014). 92Non-motor signs in genetic forms of Parkinson’s disease. In K. R. Chaudhuri, E. Tolosa, A. H. V Schapira, & W. Poewe (Eds.), Non-motor Symptoms of Parkinson’s Disease (p. 0). Oxford University Press. https://doi.org/10.1093/med/9780199684243.003.0007

Corrigan, M. H., Denahan, A. Q., Wright, C. E., Ragual, R. J., & Evans, D. L. (2000). Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety, 11(2), 58–65. https://doi.org/10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h

Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., & Sampaio, C. (2019). Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Movement Disorders : Official Journal of the Movement Disorder Society, 34(2), 180–198. https://doi.org/10.1002/mds.27602

Ceravolo, R., Nuti, A., Piccinni, A., Dell’Agnello, G., Bellini, G., Gambaccini, G., Dell’Osso, L., Murri, L., & Bonuccelli, U. (2000). Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology, 55(8), 1216–1218. https://doi.org/10.1212/wnl.55.8.1216

Leo, R. J. (1996). Movement disorders associated with the serotonin selective reuptake inhibitors. The Journal of Clinical Psychiatry, 57(10), 449–454. https://doi.org/10.4088/jcp.v57n1002

Gilat, M., Coeytaux Jackson, A., Marshall, N. S., Hammond, D., Mullins, A. E., Hall, J. M., Fang, B. A. M., Yee, B. J., Wong, K. K. H., Grunstein, R. R., & Lewis, S. J. G. (2020). Melatonin for rapid eye movement sleep behavior disorder in Parkinson’s disease: A randomised controlled trial. Movement Disorders : Official Journal of the Movement Disorder Society, 35(2), 344–349. https://doi.org/10.1002/mds.27886

Medeiros, C. A. M., Carvalhedo de Bruin, P. F., Lopes, L. A., Magalhães, M. C., de Lourdes Seabra, M., & de Bruin, V. M. S. (2007). Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled study. Journal of Neurology, 254(4), 459–464. https://doi.org/10.1007/s00415-006-0390-x

Rota, S., Boura, I., Batzu, L., Titova, N., Jenner, P., Falup-Pecurariu, C., & Chaudhuri, K. R. (2020). “Dopamine agonist Phobia” in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine. Expert Review of Neurotherapeutics, 20(9), 953–965. https://doi.org/10.1080/14737175.2020.1806059

De Matteis, L., Martín-Rapún, R., & de la Fuente, J. M. (2018). Nanotechnology in Personalized Medicine: A Promising Tool for Alzheimer’s Disease Treatment. Current Medicinal Chemistry, 25(35), 4602–4615. https://doi.org/10.2174/0929867324666171012112026

Spear, B. B., Heath-Chiozzi, M., & Huff, J. (2001). Clinical application of pharmacogenetics. Trends in Molecular Medicine, 7(5), 201–204. https://doi.org/10.1016/s1471-4914(01)01986-4

Masellis, M., Sherborn, K., Neto, P., Sadovnick, D. A., Hsiung, G.-Y. R., Black, S. E., Prasad, S., Williams, M., & Gauthier, S. (2013). Early-onset dementias: diagnostic and etiological considerations. Alzheimer’s Research & Therapy, 5(Suppl 1), S7. https://doi.org/10.1186/alzrt197

Montine, T. J., & Montine, K. S. (2015). Precision medicine: Clarity for the clinical and biological complexity of Alzheimer’s and Parkinson’s diseases. The Journal of Experimental Medicine, 212(5), 601–605. https://doi.org/10.1084/jem.20150656

Vanitallie, T. B. (2013). Preclinical sporadic Alzheimer’s disease: target for personalized diagnosis and preventive intervention. Metabolism: Clinical and Experimental, 62 Suppl 1, S30-3. https://doi.org/10.1016/j.metabol.2012.08.024

Welsh-Bohmer, K. A. (2008). Defining “prodromal” Alzheimer’s disease, frontotemporal dementia, and Lewy body dementia: are we there yet? In Neuropsychology review (Vol. 18, Issue 1, pp. 70–72). https://doi.org/10.1007/s11065-008-9057-y

Saykin, A. J., Shen, L., Yao, X., Kim, S., Nho, K., Risacher, S. L., Ramanan, V. K., Foroud, T. M., Faber, K. M., Sarwar, N., Munsie, L. M., Hu, X., Soares, H. D., Potkin, S. G., Thompson, P. M., Kauwe, J. S. K., Kaddurah-Daouk, R., Green, R. C., Toga, A. W., & Weiner, M. W. (2015). Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association, 11(7), 792–814. https://doi.org/10.1016/j.jalz.2015.05.009

Lambert, J. C., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., DeStafano, A. L., Bis, J. C., Beecham, G. W., Grenier-Boley, B., Russo, G., Thorton-Wells, T. A., Jones, N., Smith, A. V, Chouraki, V., Thomas, C., Ikram, M. A., Zelenika, D., Vardarajan, B. N., … Amouyel, P. (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nature Genetics, 45(12), 1452–1458. https://doi.org/10.1038/ng.2802

Reitz, C. (2016). Toward precision medicine in Alzheimer’s disease. Annals of Translational Medicine, 4(6), 107. https://doi.org/10.21037/atm.2016.03.05

Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006). Pharmacogenomics and individualized drug therapy. Annual Review of Medicine, 57, 119–137. https://doi.org/10.1146/annurev.med.56.082103.104724

Lauschke, V. M., Zhou, Y., & Ingelman-Sundberg, M. (2019). Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacology & Therapeutics, 197, 122–152. https://doi.org/10.1016/j.pharmthera.2019.01.002

Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O’Donovan, M., Correll, C. U., Kane, J. M., van Os, J., & Insel, T. R. (2015). Schizophrenia. Nature Reviews. Disease Primers, 1, 15067. https://doi.org/10.1038/nrdp.2015.67

Lally, J., & MacCabe, J. H. (2015). Antipsychotic medication in schizophrenia: a review. British Medical Bulletin, 114(1), 169–179. https://doi.org/10.1093/bmb/ldv017

Dzau, V., & Braunwald, E. (1991). Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. American Heart Journal, 121(4 Pt 1), 1244–1263. https://doi.org/10.1016/0002-8703(91)90694-d

Currie, G., & Delles, C. (2018). Precision Medicine and Personalized Medicine in Cardiovascular Disease. Advances in Experimental Medicine and Biology, 1065, 589–605. https://doi.org/10.1007/978-3-319-77932-4_36

Padmanabhan, S., & Joe, B. (2017). Towards Precision Medicine for Hypertension: A Review of Genomic, Epigenomic, and Microbiomic Effects on Blood Pressure in Experimental Rat Models and Humans. Physiological Reviews, 97(4), 1469–1528. https://doi.org/10.1152/physrev.00035.2016

Ladapo, J. A., Budoff, M., Sharp, D., Zapien, M., Huang, L., Maniet, B., Herman, L., & Monane, M. (2017). Clinical Utility of a Precision Medicine Test Evaluating Outpatients with Suspected Obstructive Coronary Artery Disease. The American Journal of Medicine, 130(4), 482.e11-482.e17. https://doi.org/10.1016/j.amjmed.2016.11.021

Halliday, B. P., Cleland, J. G. F., Goldberger, J. J., & Prasad, S. K. (2017). Personalizing Risk Stratification for Sudden Death in Dilated Cardiomyopathy: The Past, Present, and Future. Circulation, 136(2), 215–231. https://doi.org/10.1161/CIRCULATIONAHA.116.027134

Savoia, C., Volpe, M., Grassi, G., Borghi, C., Agabiti Rosei, E., & Touyz, R. M. (2017). Personalized medicine-a modern approach for the diagnosis and management of hypertension. Clinical Science (London, England : 1979), 131(22), 2671–2685. https://doi.org/10.1042/CS20160407

Sun, D., Liu, J., Xiao, L., Liu, Y., Wang, Z., Li, C., Jin, Y., Zhao, Q., & Wen, S. (2017). Recent development of risk-prediction models for incident hypertension: An updated systematic review. PloS One, 12(10), e0187240. https://doi.org/10.1371/journal.pone.0187240

Wen, H.-N., Wang, C.-Y., Li, J.-M., & Jiao, Z. (2021). Precision Cardio-Oncology: Use of Mechanistic Pharmacokinetic and Pharmacodynamic Modeling to Predict Cardiotoxicities of Anti-Cancer Drugs. Frontiers in Oncology, 11, 814699. https://doi.org/10.3389/fonc.2021.814699

van Timmeren, J. E., Cester, D., Tanadini-Lang, S., Alkadhi, H., & Baessler, B. (2020). Radiomics in medical imaging-"how-to" guide and critical reflection. Insights into Imaging, 11(1), 91. https://doi.org/10.1186/s13244-020-00887-2

Weldy, C. S., & Ashley, E. A. (2021). Towards precision medicine in heart failure. Nature Reviews. Cardiology, 18(11), 745–762. https://doi.org/10.1038/s41569-021-00566-9

Linschoten, M., Teske, A. J., Cramer, M. J., van der Wall, E., & Asselbergs, F. W. (2018). Chemotherapy-Related Cardiac Dysfunction: A Systematic Review of Genetic Variants Modulating Individual Risk. Circulation. Genomic and Precision Medicine, 11(1), e001753. https://doi.org/10.1161/CIRCGEN.117.001753